Pumitamig Shows Encouraging Phase 2 Efficacy in Lung Cancer, Advancing to Pivotal Phase 3
BNTX sits 24% above its 52-week low of $79.52.
Summary
BioNTech reported encouraging interim Phase 2 results for its bispecific immunomodulator, pumitamig, in advanced non-small cell lung cancer, showing high response rates and supporting its progression into pivotal Phase 3 studies.
Key Events · Product Development and Regulatory · BNTX
-
Positive Phase 2 Data for Pumitamig
Interim Phase 2 results for pumitamig (BNT327/BMS-986545) in advanced non-small cell lung cancer (NSCLC) showed encouraging efficacy and robust antitumor activity, with high objective response rates across various PD-L1 expression levels.
-
High Response Rates Observed
Confirmed objective response rates (cORR) reached 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose, with strong responses even in patients with low PD-L1 expression (47.6% for TPS ˂ 1%).
-
Advancing to Pivotal Phase 3
Pumitamig is progressing into the pivotal Phase 3 part of the ROSETTA Lung-02 trial, with two additional global Phase 3 trials also enrolling, underscoring confidence in the bispecific immunomodulator.
Analysis · BNTX · Life Sciences
BioNTech and Bristol Myers Squibb announced positive interim Phase 2 data for pumitamig in advanced non-small cell lung cancer (NSCLC). The drug demonstrated encouraging efficacy and robust antitumor activity, with high objective response rates across various PD-L1 expression levels, including in patients who typically respond poorly to existing checkpoint inhibitors. This positive clinical update for a late-stage oncology candidate is a significant development, especially following a period of negative corporate news for BioNTech, and supports the continued advancement of pumitamig into pivotal Phase 3 trials.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTX was trading at $98.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3B. The 52-week trading range was $79.52 to $124.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.